Sequenom Announces New York State Approval of a Noninvasive Prenatal Test for Rhesus D Incompatibility
"This will be the first commercially introduced noninvasive prenatal test in the United States to utilize the SEQureDx(TM) Technology and represents a significant step in our strategy to build a proprietary global portfolio of noninvasive prenatal products. RhD is our pioneering test and will serve in assisting in preparing us in developing and launching other tests such as FetalXY and Down syndrome," said Harry Stylli, Ph.D., Sequenom's President and Chief Executive Officer. "Genetic-based noninvasive prenatal testing could complement and potentially present a paradigm shift from current invasive testing procedures such as amniocentesis. Tests based on our SEQureDx Technology can be performed from a simple maternal blood sample, which could allow obstetric and fetal maternal specialists to successfully intervene early in the pregnancy to improve outcomes."
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!
Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!